Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

CHF

- PMLiVE

Amgen agrees to lower prescription drug costs in deal with US government

The company has invested $40bn in US R&D and manufacturing in the past seven years

- PMLiVE

Amgen reports positive results from landmark cardiovascular study

The study found significant reductions of major cardiovascular events in high-risk adults following treatment

- PMLiVE

Amgen commits $650m to US manufacturing expansion

The investment is expected to generate up to 750 new jobs

- PMLiVE

Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis

The phase 3 study included around 2,600 patients

- PMLiVE

Alnylam’s Amvuttra approved by MHRA to treat rare heart disease ATTR-CM

The drug has been authorised to treat both wild-type and hereditary forms of the disease

- PMLiVE

Amgen’s bemarituzumab shows promise in phase 3 gastric cancer study

Almost one million new cases of gastric cancer are diagnosed globally every year

- PMLiVE

Novartis and ProFound enter cardiovascular disease collaboration worth $750m per target

The companies will aim to discover and develop new therapeutics for the group of disorders

- PMLiVE

Alnylam shares phase 3 results for Amvuttra in rare heart disease ATTR-CM

Transthyretin amyloid cardiomyopathy is estimated to affect over 300,000 people worldwide

- PMLiVE

Novo Nordisk’s GLP-1 drug Wegovy shows early protection against heart disease

Heart and circulatory diseases are responsible for more than 170,000 deaths in the UK every year

- PMLiVE

Alnylam’s RNAi therapeutic vutrisiran recommended by CHMP for rare heart disease

The committee has recommended the drug for both wild type and hereditary ATTR-CM

- PMLiVE

Amgen’s Uplizna approved by FDA as first treatment for rare disease IgG4-RD

Immunoglobulin G4-related disease affects approximately 20,000 people in the US

- PMLiVE

Merck gains rights to Hengrui’s heart disease candidate in deal worth almost $2bn

Cardiovascular diseases result in an estimated 17.9 million global deaths each year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links